Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tolterodine
Drug ID BADD_D02244
Description Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved; investigational
ATC Code G04BD07
DrugBank ID DB01036
KEGG ID D00646
MeSH ID D000068737
PubChem ID 443879
TTD Drug ID D0BZ7W
NDC Product Code 13668-189; 13668-190; 0904-6592; 60687-330; 0904-6593; 65427-022; 60687-319
UNII WHE7A56U7K
Synonyms Tolterodine Tartrate | Tartrate, Tolterodine | Tolterodine | Detrol | Detrol LA | Urotrol | PHA-686464B | PHA 686464B | PHA686464B | Detrusitol | Unidet
Chemical Information
Molecular Formula C22H31NO
CAS Registry Number 124937-51-5
SMILES CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004---
Macular degeneration06.09.03.0010.000226%-
Memory impairment17.03.02.003; 19.20.01.0030.001379%
Micturition urgency20.02.02.0060.000882%
Milia23.02.03.0110.000226%-
Multiple sclerosis10.04.10.008; 17.16.01.0010.000339%-
Myalgia15.05.02.0010.000226%
Neoplasm malignant16.16.01.0010.000226%-
Nocturia20.02.03.0010.001764%-
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Orthostatic hypotension17.05.01.020; 24.06.03.0040.000226%-
Pain08.01.08.004--
Pain in extremity15.03.04.0100.000882%
Palpitations02.11.04.012--
Penile haemorrhage21.12.01.011; 24.07.03.018---
Penis disorder21.12.01.001---
Pollakiuria20.02.02.0070.002533%
Pruritus23.03.12.0010.002759%
Pyrexia08.05.02.0030.000565%
Rash erythematous23.03.13.0290.000226%-
Rhinorrhoea22.12.03.021--
Rotator cuff syndrome12.01.07.018; 15.01.08.0020.000339%
Scab23.03.03.0040.000226%-
Sinusitis11.01.13.005; 22.07.03.007--
Skin fissures23.03.03.008---
Sleep disorder19.02.04.0010.000498%-
Somnolence17.02.04.006; 19.02.05.0030.000724%
Swelling08.01.03.0150.000769%-
Tachycardia02.03.02.0070.000678%-
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene